Clinical Trial Update: Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating escalating dose safety of MEDI-507 in patients with graft-versus-host disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• MEDI-507

Snippet

Sponsor: MedImmune LLC | Conditions: Graft-Versus-Host Disease | Phase 1 | Status: COMPLETED